medcelerator · clinician one-pager

Monthly Shot to Lower Triglycerides and Pancreatitis Risk

Tryngolza (olezarsen) — ApoC-III ASO for severe hypertriglyceridemia (sHTG) and FCS

FDA Approved · United States · October 6, 2026

Condition: Severe Hypertriglyceridemia

Who this is for

This is for adults with severe hypertriglyceridemia (fasting TG 500 mg/dL or higher) — and caregivers — who need a labelled way to lower triglycerides and cut the risk of acute pancreatitis, and for adults with familial chylomicronemia syndrome (FCS) already on the FCS indication. It explains the 24 June 2026 FDA expansion of Tryngolza (olezarsen) for sHTG (USPI Revised 06/2026; NDA 218614/S-004), monthly subcutaneous autoinjector dosing (50 mg start for sHTG; 80 mg for FCS), CORE and CORE2 trial results, liver-enzyme monitoring, and why this is not a statin swap or a DIY import — without assuming every plan funds it. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/tryngolza-olezarsen-shtg